Background Inflammatory bowel diseases [IBD]―ulcerative colitis and Crohn's disease―are
commonly treated with biologic drugs. However, only approximately two-thirds of patients …

Background To review the frequency with which anti-TNF-α loses its effect and dose
“intensification” is required for Crohn's disease (CD) treatment. Methods Electronic …

Background & Aims Proactive monitoring of drug trough concentrations and antibodies
against drugs might help determine whether patients are likely to respond to treatment and …

Background & Aims Many physicians hesitate to recommend anti–tumor necrosis factor
(TNF) therapy for pediatric patients with inflammatory bowel disease (IBD) because of …

Abstract Background and Aims The objective was to evaluate the pharmacokinetics,
safety/tolerability, and efficacy of ustekinumab in children with moderately to severely active …

The use of biologic agents, particularly anti-tumor necrosis factor (TNF)-α, has revolutionized
the treatment of inflammatory bowel diseases (IBD), modifying their natural history. Several …

The availability of biologic therapies in inflammatory bowel disease (IBD) is increasing
significantly. This represents more options to treat patients, but also more difficulties in …

Crohn's disease in childhood causes linear growth retardation, which has a substantial
effect on management of this disease. By contrast, growth is rarely a problem in children …

Background Infliximab induces and maintains clinical remission in children with Crohn's
disease (CD), but specifically pediatric long-term data remain sparse. Methods Patients (N …

Tumor necrosis factor-α (TNF-α) antagonists, the first biologics approved for treating patients
with inflammatory bowel disease (IBD), are effective for the induction and maintenance of …